Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain - PubMed (original) (raw)
Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain
T C Saido et al. Neurosci Lett. 1996.
Abstract
We aimed to determine quantitatively the fine amino- and carboxyl-terminal structure of A beta peptides deposited in human brain using a set of 12 anti-A beta antibodies that distinguish between terminal modifications including isomerization, stereoisomerization, limited proteolysis, and cyclization. Immunochemical examination of cortical blocks from aged subjects distinguished by their total plaque load and from a young Down's syndrome patient identified the major invariantly deposited species as A beta x-42 (X = 1(D-aspartate) and 3(pyroglutamate) and/or 11(pyroglutamate)). These molecular forms, presumably representing by-products of metabolic intermediates toward degradation, are similar in being resistant to major aminopeptidases. A beta 17-42 ("p3' fragment), a major secreted form of truncated A beta with high insolubility, was found to be a minor one. A possible interpretation for these observations would be that proteolysis of A beta from its amino terminus may limit the rate of A beta catabolism.
Similar articles
- Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.
Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, Schettini G. Russo C, et al. Neurobiol Dis. 2001 Feb;8(1):173-80. doi: 10.1006/nbdi.2000.0357. Neurobiol Dis. 2001. PMID: 11162251 - Secretory cleavage site of Alzheimer amyloid precursor protein is heterogeneous in Down's syndrome brain.
Kametani F, Tanaka K, Tokuda T, Ikeda S. Kametani F, et al. FEBS Lett. 1994 Sep 5;351(2):165-7. doi: 10.1016/0014-5793(94)00851-5. FEBS Lett. 1994. PMID: 8082757 - Alzheimer beta/A4-amyloid precursor protein: evidence for putative amyloidogenic fragment.
Gandy SE, Bhasin R, Ramabhadran TV, Koo EH, Price DL, Goldgaber D, Greengard P. Gandy SE, et al. J Neurochem. 1992 Jan;58(1):383-6. doi: 10.1111/j.1471-4159.1992.tb09322.x. J Neurochem. 1992. PMID: 1345769 - Production of amyloid beta protein from normal amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial Alzheimer's disease.
Golde TE, Cai XD, Shoji M, Younkin SG. Golde TE, et al. Ann N Y Acad Sci. 1993 Sep 24;695:103-8. doi: 10.1111/j.1749-6632.1993.tb23036.x. Ann N Y Acad Sci. 1993. PMID: 8239266 Review. - Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease.
Tomita T. Tomita T. Adv Biol Regul. 2017 May;64:33-38. doi: 10.1016/j.jbior.2017.01.001. Epub 2017 Jan 5. Adv Biol Regul. 2017. PMID: 28082052 Review.
Cited by
- Serine phosphorylation mimics of Aβ form distinct, non-cross-seeding fibril morphs.
Sanagavarapu K, Meisl G, Lattanzi V, Bernfur K, Frohm B, Olsson U, Knowles TPJ, Malmendal A, Linse S. Sanagavarapu K, et al. Chem Sci. 2024 Oct 11. doi: 10.1039/d3sc06343g. Online ahead of print. Chem Sci. 2024. PMID: 39494375 Free PMC article. - Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab.
Iwata N, Tsubuki S, Sekiguchi M, Watanabe-Iwata K, Matsuba Y, Kamano N, Fujioka R, Takamura R, Watamura N, Kakiya N, Mihira N, Morito T, Shirotani K, Mann DM, Robinson AC, Hashimoto S, Sasaguri H, Saito T, Higuchi M, Saido TC. Iwata N, et al. Life Sci Alliance. 2024 Sep 30;7(12):e202402650. doi: 10.26508/lsa.202402650. Print 2024 Dec. Life Sci Alliance. 2024. PMID: 39348937 Free PMC article. - Alzheimer's disease linked Aβ42 exerts product feedback inhibition on γ-secretase impairing downstream cell signaling.
Zoltowska KM, Das U, Lismont S, Enzlein T, Maesako M, Houser MCQ, Franco ML, Özcan B, Gomes Moreira D, Karachentsev D, Becker A, Hopf C, Vilar M, Berezovska O, Mobley W, Chávez-Gutiérrez L. Zoltowska KM, et al. Elife. 2024 Jul 19;12:RP90690. doi: 10.7554/eLife.90690. Elife. 2024. PMID: 39027984 Free PMC article. - Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease.
Grenon MB, Papavergi MT, Bathini P, Sadowski M, Lemere CA. Grenon MB, et al. Int J Mol Sci. 2024 May 25;25(11):5754. doi: 10.3390/ijms25115754. Int J Mol Sci. 2024. PMID: 38891941 Free PMC article. - Synthesis and Evaluation of a Novel PET Radioligand for Imaging Glutaminyl Cyclase Activity as a Biomarker for Detecting Alzheimer's Disease.
Behof WJ, Haynes JR, Whitmore CA, Cheung YY, Tantawy MN, Peterson TE, Wijesinghe P, Matsubara JA, Pham W. Behof WJ, et al. ACS Sens. 2024 May 24;9(5):2605-2613. doi: 10.1021/acssensors.4c00313. Epub 2024 May 8. ACS Sens. 2024. PMID: 38718161 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources